Unexpected out-of-network charges targeted by California bill

California legislators have until Aug. 31 to act on legislation aimed at “surprise” medical charges incurred when a specialist isn’t included in a patient’s insurance network.

STAT’s Casey Ross reports this is the second attempt by California Assemblyman Rob Bonta to pass such a bill. The last version would’ve paid these out-of-network physicians 100 percent of the Medicare reimbursement for these services, which has been increased to 125 percent in the current proposal. That’s still not good enough, according to some doctors.

“Access to care will suffer,” said acute care surgeon Eileen Natuzzi, MD. “If my fees are capped or some of my associates fees are capped and it’s not [financially] feasible, then the number of surgeons and specialists available will decrease.”

Independent physicians argue the legislation would only encourage insurers to further narrow their networks, but Bonta said the bill would allow doctors to appeal payments to an independent panel if they’re unsatisfied.

“We’re creating a reasonable, practical approach to ensure that (physicians) get a minimum reimbursement that is a strong starting point,” Bonta said.

New York and Florida have already enacted similar laws. For more on the battle between physicians and insurers over the California bill, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.